Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
NATICK, Mass., July 31, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing first-in-class nuclear transport modulators for the treatment of cancer and other major diseases, today announced the initiation of a Phase 1b clinical trial of its lead product candidate oral SINE Selinexor (KPT-330) in patients with advanced soft tissue or bone sarcomas. SINE compounds specifically and irreversibly inhibit the nuclear export protein Exportin 1 (XPO1 or CRM1), forcing the nuclear localization and activation of multiple tumor suppressor proteins. This XPO1 inhibition leads to selective killing of tumor cells, while sparing normal cells. Selinexor is the first oral SINE XPO1 antagonist to enter human clinical trials.
Help employers find you! Check out all the jobs and post your resume.
NATICK, Mass., July 31, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing first-in-class nuclear transport modulators for the treatment of cancer and other major diseases, today announced the initiation of a Phase 1b clinical trial of its lead product candidate oral SINE Selinexor (KPT-330) in patients with advanced soft tissue or bone sarcomas. SINE compounds specifically and irreversibly inhibit the nuclear export protein Exportin 1 (XPO1 or CRM1), forcing the nuclear localization and activation of multiple tumor suppressor proteins. This XPO1 inhibition leads to selective killing of tumor cells, while sparing normal cells. Selinexor is the first oral SINE XPO1 antagonist to enter human clinical trials.
Help employers find you! Check out all the jobs and post your resume.
